Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment

(2014) Kevin Damman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis

(2013) K. Damman et al.   EUROPEAN HEART JOURNAL

The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

(2013) Adriaan A Voors et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence?

(2013) João Victor Salgado et al.   Journal of Cardiology

Clinical Utility of Biomarkers in Premature Atherosclerosis

(2012) A.-M. Kampoli et al.   CURRENT MEDICINAL CHEMISTRY

The role of the kidney in heart failure

(2012) M. Metra et al.   EUROPEAN HEART JOURNAL

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure

(2012) Orly Vardeny et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

Prognostic Importance of Early Worsening Renal Function After Initiation of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Cardiac Dysfunction

(2011) Jeffrey M. Testani et al.   Circulation-Heart Failure

Serum cystatin C-based equation compared to serum creatinine-based equations for estimation of glomerular filtration rate in patients with chronic kidney disease

(2011) R. Hojs et al.   CLINICAL NEPHROLOGY

Use of cystatin C levels in estimating renal function and prognosis in patients with chronic systolic heart failure

(2011) Kevin Damman et al.   HEART

The Cardiorenal Syndrome in Heart Failure

(2011) Kevin Damman et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Cystatin C and cardiac hypertrophy in primary hypertension

(2010) Merche Prats et al.   BLOOD PRESSURE

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

The plasma bradykinin-forming pathways and its interrelationships with complement

(2010) Allen P. Kaplan et al.   MOLECULAR IMMUNOLOGY

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

(2009) Jessie Gu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction

(2008) Barry M. Massie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade

(2008) Ron Blankstein et al.   Heart Failure Clinics